

Disease Progression in Women With X-linked Adrenoleukodystrophy

NCT06178120

Status RECRUITING
Sponsor Minoryx Therapeutics, S.L.
Enrollment 40 participants

Key Eligibility Criteria

Inclusion (5)

- Women aged 18 years old or older.
- Diagnosis of X-linked ALD based on genetic testing, altered VLCFA levels, or family history.
- Willing to undergo annual follow-up visits, including brain and spinal cord MRI scans.
- Provision of written informed consent.
- Affiliation or beneficiary of a French social security system or of such a regime.

Exclusion (5)

- Any condition that in the opinion of the investigator are likely to adversely affect the study participation, interfere with study compliance, or confound the study results.
- Under treatment or previous treatment with leriglitzone.
- Pregnant or lactating women.
- Subjects benefiting from laws aimed at protecting vulnerable adults: subjects being deprived of liberty by judicial or administrative decision, subjects under guardianship.
- Participation in an interventional clinical trial.

Locations (1 total)

Paris Brain Institute (ICM) Centre Hospitalier Universitaire Pitié Salpêtrière, Paris, France